Abiraterone and enzalutamide improve survival for patients with metastatic castration resistant prostate cancer1,2. Unfortunately, 20-40% of patients have primary resistance abiraterone or enzalutamide, and essentially all patients develop secondary resistance3. Various mechanisms have been postulated for why patients develop cross resistance – one of which being the presence of androgen receptor splice variants. In particular, androgen-receptor splice variant 7 messenger RNA (AR-V7) has been well defined by as a variant which is associated with resistance to enzalutamide and abiraterone. Antonarakis and colleagues demonstrated prospectively that in a cohort of patients receiving enzalutamide, 53% of AR-V7 negative patients had a response compared to 0% of AR-V7 positive patients3.
In this small phase I study, Dr. Pan and colleagues utilized niclosamide in combination with abiraterone in patients with progressive castration resistant prostate cancer. Niclosamide, a salicylamide derivative, was originally an anti-helminthic drug but more recently has been explored in variety of malignancies including HCC, colon cancer, and ovarian cancer4-7. In ovarian cancer cell lines, niclosamide may impact the Wnt/beta-catenin, mTOR, and STAT3 pathways.
6 patients were treated with niclosamide/PDMX1001 at a dose of 1600 mg TID without any dose limiting toxicities. This is the dose that will be used as the phase II dose. At this dose, the trough was at least three times the target level of niclosamide. Of the 6 patients, two have had undetectable PSAs for 16 cycles with ongoing activity and two patients have a partial response with more than 50% PSA decline. One limitation to this study is the lack of a control arm – patients were compared against historical controls. A second limitation to this study is that abiraterone is highly active in this patients and it difficult to say if these patients would have had the same response without niclosamide.
The next step will be to test if niclosamide will be effective in the population of patients who have disease refractory to enzalutamide or abiraterone. Per Dr. Pan, the phase II study began enrolling patients last week and they will plan to enroll only patients who have progressed on enzalutamide.
Presented By: Chong-xian Pan, MD, PhD. University of California Davis Comprehensive Cancer Center
Written by: Jason Zhu, MD Fellow, Division of Hematology and Oncology Duke University Medical Center, Twitter: @TheRealdJasonZhu at the 2018 ASCO Annual Meeting – June 1-5, 2018 – Chicago, IL USA
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.